RecruitingNot Applicable

The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy

China400 participantsStarted 2025-10-07

Plain-language summary

This study aims to examine the predictive value of metastatic gastric mesenteries, which contains metastatic lymph node, in 6 gastric mesenteries; and importantly, to further evaluate the relationship between the number of metastatic gastric mesenteries and prognosis in the gastric cancer patients who received D2+complete mesogastric excision (CME).

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged older than 18 years and younger than 85 years
✓. Primary gastric adenocarcinoma confirmed by preoperative pathology result
✓. cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition
✓. Patients who received gastrectomy with D2 lymphadenectomy plus complete mesogastric excision
✓. American Society of Anesthesiologists (ASA) class I, II, or III
✓. Written informed consent

Exclusion criteria

✕. Negative preoperative biopsy
✕. Too late tumour stage or metastasis (cT4b/M1)
✕. BMI\>30 kg/m2
✕. Total gastrectomy or proximal gastrectomy
✕. previous neoadjuvant chemotherapy or radiotherapy
✕. Previous upper abdominal surgery
✕. Combined with other malignant diseases
✕. Reject operation

What they're measuring

overall survival

Timeframe: through study completion, an average of 3 year

Trial details

NCT IDNCT07139418

SponsorJichao Qin

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-08-30

Contact for this trial

Tao Wang, Ph.d

+86-197-068-25286 15002740874@163.com

View on ClinicalTrials.gov More Gastric Carcinoma trials